Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PHARMACOKINETICS AND RADIATION-DOSIMETRY OF TC-99(M)-LABELED MONOCLONAL-ANTIBODY B43.13 IN OVARIAN-CANCER PATIENTS
Autore:
MCQUARRIE SA; BAUM RP; NIESEN A; MADIYALAKAN R; KORZ W; SYKES TR; SYKES CJ; HOR G; MCEWAN AJB; NOUJAIM AA;
Indirizzi:
UNIV ALBERTA,FAC PHARM & PHARMACEUT SCI EDMONTON AB T6G 2N8 CANADA
Titolo Testata:
Nuclear medicine communications
fascicolo: 9, volume: 18, anno: 1997,
pagine: 878 - 886
SICI:
0143-3636(1997)18:9<878:PAROTM>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-MARKERS; TC-99M;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
22
Recensione:
Indirizzi per estratti:
Citazione:
S.A. Mcquarrie et al., "PHARMACOKINETICS AND RADIATION-DOSIMETRY OF TC-99(M)-LABELED MONOCLONAL-ANTIBODY B43.13 IN OVARIAN-CANCER PATIENTS", Nuclear medicine communications, 18(9), 1997, pp. 878-886

Abstract

OVAREX(TM) MAb B43.13 is a new radiopharmaceutical based on a monoclonal antibody (MAb-B43.13) known to recognize CA 125, a tumour antigen associated with epithelial ovarian cancer. This MAb is capable of facile radiolabelling with Tc-99(m) and has been shown previously to localize in the tumours of ovarian cancer patients. The present study was initiated to measure the pharmacokinetics of this MAb in the serum of 10 patients with primary or metastatic ovarian cancer. A two-compartment model was found to be best at representing the biodistribution of the Tc-99(m)-labelled MAb, yielding a 2.6 h distribution phase half-Lifeand a 31.3 h elimination phase half-life. The serum and renal clearances for Tc-99(m)- MAb-B43.13 were 221 and 53 mi h(-1) respectively. These parameters were compared with a similar model developed from the serum values of the MAb itself (determined using an ELISA detection method). Based on the serum pharmacokinetics of (99)Tc(m-)MAb-B43.13 and whole-body planar gamma camera images, an estimate of the radiation dose from Tc-99(m) was calculated using standard MIRD schema. The organsdemonstrating significant Tc-99(m) uptake included the Liver, kidneys, heart and spleen. The whole body dose was similar to other Tc-99(m)-labelled MAbs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/01/20 alle ore 19:44:47